# BIOMONDE LARVAL DEBRIDEMENT THERAPY PRODUCTS, LARVAE 100/200/300 AND BIOBAG 50/100/200/300/400 (K142020) BioMonde Larval Debridement Therapy Products - BioBag 50/100/200/300/400 BioMonde Larval Debridement Therapy Products - BioBag 50/100/200/300/400 (K142020) (BK251219)

_BioMonde · Nov 5, 2014 · SESE_

**Canonical URL:** https://fda-staging.innolitics.com/device/BK251219

## Device Facts

- **Applicant:** BioMonde
- **Decision Date:** Nov 5, 2014
- **Decision:** SESE

---

**Source:** [https://fda-staging.innolitics.com/device/BK251219](https://fda-staging.innolitics.com/device/BK251219)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com